Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Publication ,  Journal Article
Goepfert, PA; Elizaga, ML; Sato, A; Qin, L; Cardinali, M; Hay, CM; Hural, J; DeRosa, SC; DeFawe, OD; Tomaras, GD; Montefiori, DC; Xu, Y ...
Published in: J Infect Dis
March 1, 2011

BACKGROUND: Recombinant DNA and modified vaccinia virus Ankara (rMVA) vaccines represent a promising approach to an HIV/AIDS vaccine. This Phase 1 clinical trial compared the safety and immunogenicity of a rMVA vaccine administered with and without DNA vaccine priming METHODS: GeoVax pGA2/JS7 DNA (D) and MVA/HIV62 (M) vaccines encode noninfectious virus-like particles. Intramuscular needle injections were used to deliver placebo, 2 doses of DNA followed by 2 doses of rMVA (DDMM), one dose of DNA followed by 2 doses of rMVA (DMM), or 3 doses of rMVA (MMM) to HIV-seronegative participants. RESULTS: Local and systemic symptoms were mild or moderate. Immune response rates for CD4 + and CD8 + T cells were highest in the DDMM group and lowest in the MMM group (77% vs 43% CD4 + and 42% vs 17% CD8 +). In contrast, response rates for Env binding and neutralizing Ab were highest in the MMM group. The DMM group had intermediate response rates. A 1/10th-dose DDMM regimen induced similar T cell but reduced Ab response rates compared with the full-dose DDMM. CONCLUSIONS: MVA62 was well tolerated and elicited different patterns of T cell and Ab responses when administered alone or in combination with the JS7 DNA vaccine.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Infect Dis

DOI

EISSN

1537-6613

Publication Date

March 1, 2011

Volume

203

Issue

5

Start / End Page

610 / 619

Location

United States

Related Subject Headings

  • Young Adult
  • Vaccinia virus
  • Vaccines, DNA
  • United States
  • Placebos
  • Middle Aged
  • Microbiology
  • Male
  • Humans
  • HIV-1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goepfert, P. A., Elizaga, M. L., Sato, A., Qin, L., Cardinali, M., Hay, C. M., … National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network, . (2011). Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis, 203(5), 610–619. https://doi.org/10.1093/infdis/jiq105
Goepfert, Paul A., Marnie L. Elizaga, Alicia Sato, Li Qin, Massimo Cardinali, Christine M. Hay, John Hural, et al. “Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.J Infect Dis 203, no. 5 (March 1, 2011): 610–19. https://doi.org/10.1093/infdis/jiq105.
Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2011 Mar 1;203(5):610–9.
Goepfert, Paul A., et al. “Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.J Infect Dis, vol. 203, no. 5, Mar. 2011, pp. 610–19. Pubmed, doi:10.1093/infdis/jiq105.
Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL, National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2011 Mar 1;203(5):610–619.
Journal cover image

Published In

J Infect Dis

DOI

EISSN

1537-6613

Publication Date

March 1, 2011

Volume

203

Issue

5

Start / End Page

610 / 619

Location

United States

Related Subject Headings

  • Young Adult
  • Vaccinia virus
  • Vaccines, DNA
  • United States
  • Placebos
  • Middle Aged
  • Microbiology
  • Male
  • Humans
  • HIV-1